Posted 4th June 2018 by Anna Gomez
qPCR and dPCR are mature analytical methods for quantifying selected genetic materials in a sample. Both utilise the PCR method to amplify amounts as small as a single molecular fragment (template) to levels where they can be easily detected, usually by fluorescence techniques.
Posted 30th May 2018 by Anna Gomez
The global qPCR & dPCR instrumentation market is growing and is expected to reach 1631.09 million USD by the end of 2025.
Posted 14th May 2018 by Anna Gomez
Our understanding of the aberrant biological pathways (oncogenic pathways) that are involved in the formation and progression of cancers has increased with huge leaps in the last decades of cancer research. The ever-increasing knowledge was and still is accompanied by the development of increasing numbers of precision drugs, tailored to neutralize these aberrations.
Posted 23rd April 2018 by Anna Gomez
The Digital PCR track at the 4Bio Summit covered the benefits and future development of dPCR, comparisons between dPCR and qPCR and other technologies such as NGS, strategies to convert to a dPCR platform and applying the technology to precision medicine.
If you weren’t able to attend the 4Bio Summit, enjoy these free slides from Ward De Speigelaere, Anthony Magliocco and Nasrin Sarafan-Vasseur.
Posted 21st March 2018 by Anna Gomez
Precision medicine in oncology requires matching each patient with treatment personalised to their genes and often the proteomic profile of their cancer. Liquid biopsies continue to gain grounds as a tool for diagnostic testing in oncology.
Posted 6th March 2018 by Kate Barlow
Guro E. Lind is a group leader at the Institute for Cancer Research, Oslo University Hospital and a professor at the University of Oslo. We caught up with her at the 4Bio Summit to find out what she thinks needs to be done to achieve gender equality for women in STEM.
Posted 2nd March 2018 by Kate Barlow
Dr. Catherine Kibirige currently works with the Human Immunology Laboratory of the International AIDS Vaccine Initiative in London, developing new assays and methodologies for their research.
Here, she takes us through her day, her research, and her advice for young women pursuing a career in science.
The Future of Droplet Digital PCR and Blood-Based Assays: An Interview with Gary Pestano and Hestia Mellert
Posted 26th January 2018 by Kate Barlow
We caught up with Dr. Gary Pestano, VP, Development and Operations, Biodesix, and Dr. Hestia Mellert, Director, Development, Biodesix, at the 5th qPCR and Digital PCR Congress at 4Bio, where we discussed novel applications, single-cell technology, and the future of ddPCR and PCR.